Journal Article (Letter)

DKFZ-2024-01199

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Jaramillo, S. ; Krisam, J. ; Le Cornet, L.DKFZ* ; Kratzmann, M.DKFZ* ; Baumann, L. ; Eissymont, O. ; Crysandt, M. ; Görner, M. ; Kayser, S.DKFZ* ; Krause, S. ; Schliemann, C. ; Gaska, T. ; Kaufmann, M. ; Chemnitz, J. ; Schaich, M. ; Hoellein, A. ; Platzbecker, U. ; Kieser, M. ; Müller-Tidow, C. ; Schlenk, R. (Last author)DKFZ*

2024
Ferrata Storti Foundation Pavia

This record in other databases:

Please use a persistent id in citations: doi:10.3324/haematol.2023.284346

Keyword(s): Humans (MeSH) ; Gemtuzumab: therapeutic use (MeSH) ; Gemtuzumab: administration & dosage (MeSH) ; Leukemia, Myeloid, Acute: drug therapy (MeSH) ; Leukemia, Myeloid, Acute: diagnosis (MeSH) ; Antineoplastic Combined Chemotherapy Protocols: therapeutic use (MeSH) ; Antineoplastic Combined Chemotherapy Protocols: adverse effects (MeSH) ; Aminoglycosides: therapeutic use (MeSH) ; Aminoglycosides: administration & dosage (MeSH) ; Double-Blind Method (MeSH) ; Male (MeSH) ; Female (MeSH) ; Middle Aged (MeSH) ; Remission Induction (MeSH) ; Aged (MeSH) ; Induction Chemotherapy (MeSH) ; Adult (MeSH) ; Treatment Outcome (MeSH) ; Benzimidazoles (MeSH) ; Phenylurea Compounds (MeSH) ; Gemtuzumab ; Aminoglycosides ; glasdegib ; Benzimidazoles ; Phenylurea Compounds

Note: #LA:W010#

---

Contributing Institute(s):

1. Klinische Studienzentrale (W010)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---